Literature DB >> 33157050

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.

Wei Zhao1, Jun Li2, Mei-Ju M Chen2, Yikai Luo3, Zhenlin Ju2, Nicole K Nesser4, Katie Johnson-Camacho4, Christopher T Boniface4, Yancey Lawrence4, Nupur T Pande4, Michael A Davies5, Meenhard Herlyn6, Taru Muranen7, Ioannis K Zervantonakis8, Erika von Euw9, Andre Schultz2, Shwetha V Kumar2, Anil Korkut2, Paul T Spellman4, Rehan Akbani2, Dennis J Slamon9, Joe W Gray10, Joan S Brugge7, Yiling Lu11, Gordon B Mills12, Han Liang13.   

Abstract

Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed expression profiles of ∼210 clinically relevant proteins in >12,000 cancer cell line samples in response to ∼170 drug compounds using reverse-phase protein arrays. We show that integrating perturbed protein response signals provides mechanistic insights into drug resistance, increases the predictive power for drug sensitivity, and helps identify effective drug combinations. We build a systematic map of "protein-drug" connectivity and develop a user-friendly data portal for community use. Our study provides a rich resource to investigate the behaviors of cancer cells and the dependencies of treatment responses, thereby enabling a broad range of biomedical applications.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biomarker; cancer signaling pathway; drug response; protein array

Mesh:

Substances:

Year:  2020        PMID: 33157050      PMCID: PMC7738392          DOI: 10.1016/j.ccell.2020.10.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  12 in total

1.  MECHANISTIC AND DATA-DRIVEN MODELS OF CELL SIGNALING: TOOLS FOR FUNDAMENTAL DISCOVERY AND RATIONAL DESIGN OF THERAPY.

Authors:  Paul J Myers; Sung Hyun Lee; Matthew J Lazzara
Journal:  Curr Opin Syst Biol       Date:  2021-06-09

Review 2.  Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.

Authors:  Marilyne Labrie; Joan S Brugge; Gordon B Mills; Ioannis K Zervantonakis
Journal:  Nat Rev Cancer       Date:  2022-03-09       Impact factor: 69.800

3.  Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments.

Authors:  Shuang Wu; Shihai Liu; Yan Li; Changchang Liu; Huazheng Pan
Journal:  Front Cell Dev Biol       Date:  2022-05-13

4.  Transcriptome analysis and prognostic model construction based on splicing profiling in glioblastoma.

Authors:  Jiting Qiu; Chunhui Wang; Hongkang Hu; Sarah Chen; Xuehua Ding; Yu Cai
Journal:  Oncol Lett       Date:  2020-12-20       Impact factor: 2.967

Review 5.  High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery.

Authors:  Jessica M Zielinski; Jason J Luke; Silvia Guglietta; Carsten Krieg
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 8.786

6.  Bothrops Jararaca Snake Venom Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines.

Authors:  Carolina Yukiko Kisaki; Stephanie Santos Suehiro Arcos; Fabio Montoni; Wellington da Silva Santos; Hamida Macêdo Calacina; Ismael Feitosa Lima; Daniela Cajado-Carvalho; Emer Suavinho Ferro; Milton Yutaka Nishiyama-Jr; Leo Kei Iwai
Journal:  Toxins (Basel)       Date:  2021-07-25       Impact factor: 4.546

7.  Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.

Authors:  J J David Ho; Tyler A Cunningham; Paola Manara; Caroline A Coughlin; Artavazd Arumov; Evan R Roberts; Ashanti Osteen; Preet Kumar; Daniel Bilbao; Jonathan R Krieger; Stephen Lee; Jonathan H Schatz
Journal:  Cell Rep       Date:  2021-10-12       Impact factor: 9.423

8.  Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics.

Authors:  Alexandra Franz; Fabian Coscia; Ciyue Shen; Lea Charaoui; Matthias Mann; Chris Sander
Journal:  J Ovarian Res       Date:  2021-10-22       Impact factor: 4.234

9.  Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Authors:  Isabelle Rose Leo; Luay Aswad; Matthias Stahl; Elena Kunold; Frederik Post; Tom Erkers; Nona Struyf; Georgios Mermelekas; Rubin Narayan Joshi; Eva Gracia-Villacampa; Päivi Östling; Olli P Kallioniemi; Katja Pokrovskaja Tamm; Ioannis Siavelis; Janne Lehtiö; Mattias Vesterlund; Rozbeh Jafari
Journal:  Nat Commun       Date:  2022-03-30       Impact factor: 14.919

10.  A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer.

Authors:  Chen Yang; Hailin Zhang; Mengnuo Chen; Siying Wang; Ruolan Qian; Linmeng Zhang; Xiaowen Huang; Jun Wang; Zhicheng Liu; Wenxin Qin; Cun Wang; Hualian Hang; Hui Wang
Journal:  Elife       Date:  2022-02-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.